A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China

OBJECTIVE: The effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medical Products Administration. The purpose of this study was to assess the cost-effectiveness of sugem...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Wan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234548/
https://www.ncbi.nlm.nih.gov/pubmed/37262075
http://dx.doi.org/10.1371/journal.pone.0286595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234548/
https://www.ncbi.nlm.nih.gov/pubmed/37262075
http://dx.doi.org/10.1371/journal.pone.0286595

Ejemplares similares